Cancer Research



Rockland produces, validates, and distributes a diverse collection of highly-characterized melanoma cell line models. Because they are biologically stable in terms of gene expression pattern, tumor architecture, and mutation status, these models have the ability to predict clinical activity. They can also serve as individualized experimental models, which is useful for drug treatment and outcome. Originally sourced by Dr. Meenhard Herlyn of The Wistar Institute, this collection has been characterized to confirm a match to the originating patient tumor tissue via mRNA, qPCR, and DNA short tandem repeat (STR) analysis.